

Product Name: MSDC-0160 Revision Date: 01/10/2021

## **Product Data Sheet**

### **MSDC-0160**

**Cat. No.:** B3702

CAS No.: 146062-49-9


**Formula:** C19 H18 N2 O4 S

M.Wt: 370.42

Synonyms:

Target: Others
Pathway: Others

Storage: Store at -20°C



# Solvent & Solubility

≥37 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

In Vitro

Preparing Stock Solutions	Solvent  Concentration	1mg	5mg	10mg
	1 mM	2.6996 mL	13.4982 mL	26.9964 mL
	5 mM	0.5399 mL	2.6996 mL	5.3993 mL
	10 mM	0.2700 mL	1.3498 mL	2.6996 mL

Please refer to the solubility information to select the appropriate solvent.

# **Biological Activity**

Sno	rtsu	mm	ary	

mTOT-modulating insulin sensitizer

IC<sub>50</sub> & Target

#### **Cell Viability Assay**

In Vitro

10"	Figure 20
Cell Line:	LUHMES cells
Preparation method:	Limited solubility. General tips for obtaining a higher concentration: Please
	warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for
	a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	10 or 100 μM, 1 hour

-				
	Applications:	MSDC-0160 (10 μM) pretreatment (1 hour) prevented the MPP+ (10		
		μM)-induced loss of both tyrosine hydroxylase (TH)-immunoreactive		
		differentiated Lund human mesencephalic (LUHMES) cells. MSDC-0160		
		protected TH-immunoreactive neurons. MSDC-0160 counteracted both		
		MPP+-induced shortening of neurite length and reduced branching in both		
	APE BIO	LUHMES cells. MSDC-0160 (10 or 100 µM) prevented the loss of		
		GFP-fluorescent dopaminergic neurons induced by MPP+ (0.75 mM) in		
		nematodes. MSDC-0160 (10 μM) blocked LPS-induced increases in iNOS		
		expression in BV2 cell lysates.		
	Animal experiment			
	Animal models:	MPTP mouse model of Parkinson's disease (PD), En1+/- genetic mouse		
		model of PD		
	Dosage form:	Oral administration, 30 mg/kg per day		
	Applications:	MSDC-0160 (30 mg/kg per day, p.o.) treatment for 3 days after MPTP injection		
		improved motor behavior, protects nigrostriatal neurons, and suppressed		
		disease progression in the MPTP mouse model of Parkinson's disease (PD).		
In Vivo		MSDC-0160 improved motor behavior in the open-field and rotarod tests and		
		prevented dopaminergic neurodegeneration in the En1+/- genetic mouse		
		model of PD. MSDC-0160 modulated mTOR signaling in C. elegans and the		
		MPTP mouse model of PD. MSDC-0160 down-regulated mTOR signaling and		
		restored autophagy in the En1+/- genetic mouse model of PD.		
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may		
		slightly differ with the theoretical value. This is caused by an experimental		
	210	system error and it is normal.		

# **Product Citations**

See more customer validations on www.apexbt.com.

#### References

[1]. Rohatgi N, Aly H, Marshall C A, et al. Novel insulin sensitizer modulates nutrient sensing pathways and maintains  $\beta$ -cell phenotype in human islets. PloS one, 2013, 8(5): e62012.

#### Caution

FOR RESEARCH PURPOSES ONLY.



#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

#### **APExBIO Technology**

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com









